Literature DB >> 20497909

Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease.

Katarina Kågedal1, Woojin Scott Kim, Hanna Appelqvist, Sharon Chan, Danni Cheng, Lotta Agholme, Kevin Barnham, Heather McCann, Glenda Halliday, Brett Garner.   

Abstract

The Niemann-Pick type C1 (NPC1) protein mediates the trafficking of cholesterol from lysosomes to other organelles. Mutations in the NPC1 gene lead to the retention of cholesterol and other lipids in the lysosomal compartment, and such defects are the basis of NPC disease. Several parallels exist between NPC disease and Alzheimer's disease (AD), including altered cholesterol homeostasis, changes in the lysosomal system, neurofibrillary tangles, and increased amyloid-beta generation. How the expression of NPC1 in the human brain is affected in AD has not been investigated so far. In the present study, we measured NPC1 mRNA and protein expression in three distinct regions of the human brain, and we revealed that NPC1 expression is upregulated at both mRNA and protein levels in the hippocampus and frontal cortex of AD patients compared to control individuals. In the cerebellum, a brain region that is relatively spared in AD, no difference in NPC1 expression was detected. Similarly, murine NPC1 mRNA levels were increased in the hippocampus of 12-month-old transgenic mice expressing a familial AD form of human amyloid-beta precursor protein (APP) and presenilin-1 (APP/PS1tg) compared to 12-month-old wild type mice, whereas no change in NPC1 was detected in mouse cerebellum. Immunohistochemical analysis of human hippocampus indicated that NPC1 expression was strongest in neurons. However, in vitro studies revealed that NPC1 expression was not induced by transfecting SK-N-SH neurons with human APP or by treating them with oligomeric amyloid-beta peptide. Total cholesterol levels were reduced in hippocampus from AD patients compared to control individuals, and it is therefore possible that the increased expression of NPC1 is linked to perturbed cholesterol homeostasis in AD. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497909     DOI: 10.1016/j.bbalip.2010.05.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  16 in total

Review 1.  Neuropsychological assessment in Niemann-Pick disease type C: a systematic review.

Authors:  Giuseppa Maresca; Caterina Formica; Vanessa Nocito; Desiree Latella; Simona Leonardi; Maria Cristina De Cola; Giuseppe Triglia; Placido Bramanti; Francesco Corallo
Journal:  Neurol Sci       Date:  2021-05-22       Impact factor: 3.307

2.  Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C.

Authors:  Niklas Mattsson; Henrik Zetterberg; Simona Bianconi; Nicole M Yanjanin; Rao Fu; Jan-Eric Månsson; Forbes D Porter; Kaj Blennow
Journal:  JIMD Rep       Date:  2011-09-28

3.  Amyloid-β metabolism in Niemann-Pick C disease models and patients.

Authors:  Niklas Mattsson; Maria Olsson; Mikael K Gustavsson; Marko Kosicek; Martina Malnar; Jan-Eric Månsson; Maria Blomqvist; Johan Gobom; Ulf Andreasson; Gunnar Brinkmalm; Charles Vite; Silva Hecimovic; Caroline Hastings; Kaj Blennow; Henrik Zetterberg; Erik Portelius
Journal:  Metab Brain Dis       Date:  2012-09-01       Impact factor: 3.584

4.  APP overexpression in the absence of NPC1 exacerbates metabolism of amyloidogenic proteins of Alzheimer's disease.

Authors:  Mahua Maulik; Kyle Peake; JiYun Chung; Yanlin Wang; Jean E Vance; Satyabrata Kar
Journal:  Hum Mol Genet       Date:  2015-10-03       Impact factor: 6.150

Review 5.  FKBP immunophilins and Alzheimer's disease: a chaperoned affair.

Authors:  Weihuan Cao; Mary Konsolaki
Journal:  J Biosci       Date:  2011-08       Impact factor: 1.826

Review 6.  Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches.

Authors:  Anton I Rosenbaum; Frederick R Maxfield
Journal:  J Neurochem       Date:  2011-01-07       Impact factor: 5.372

Review 7.  Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin.

Authors:  Jean E Vance; Barbara Karten
Journal:  J Lipid Res       Date:  2014-03-24       Impact factor: 5.922

Review 8.  Glutathione and mitochondria.

Authors:  Vicent Ribas; Carmen García-Ruiz; José C Fernández-Checa
Journal:  Front Pharmacol       Date:  2014-07-01       Impact factor: 5.810

9.  Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.

Authors:  Jiaqi Yao; Daniel Ho; Noel Y Calingasan; Nina H Pipalia; Michael T Lin; M Flint Beal
Journal:  J Exp Med       Date:  2012-12-03       Impact factor: 14.307

10.  Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's disease.

Authors:  Andrea Armstrong; Niklas Mattsson; Hanna Appelqvist; Camilla Janefjord; Linnea Sandin; Lotta Agholme; Bob Olsson; Samuel Svensson; Kaj Blennow; Henrik Zetterberg; Katarina Kågedal
Journal:  Neuromolecular Med       Date:  2013-10-08       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.